2004TransplantationRequires access

INHIBITION OF THE IMMUNOMODULATORY ENZYME INDOLEAMINE 2,3–DIOXYGENASE ACCELERATES ALLOGRAFT REJECTION.

Gerald Brandacher, Stefan Schneeberger, Walter Mark, Peter Obrist, Ernst R. Werner, R. Margreiter, Dietmar Fuchs

Open publisher page 0 citations

Abstract

P1142 Aims: Indoleamine 2,3-dioxygenase (IDO) via tryptophan depletion and the production of proapoptotic metabolites inhibits T-cell proliferation and leads to T-cell anergy. IDO is activated by INF-γ and has been demonstrated to play an essential role in maternal tolerance. The role of IDO in solid organ transplantation has not been clarified yet. Methods: Hearts of C57BL/10 (H-2b) mice were transplanted to C3H/He (H-2k) recipients. Syngeneic transplants and allograft recipients treated with CsA or with the IDO inhibitor 1-methyl tryptophan (1-MT) served as controls. Serum concentrations of kynurenine and tryptophan were analyzed by high performance liquid chromatography (HPLC) 2, 4, 6 and 8 days following transplantation. Kynurenine to tryptophan ratios (kyn/trp) were calculated as an indirect estimate of IDO activity. Intragraft IDO mRNA expression was assessed by quantitative RT-PCR (Taqman technology). Results: Untreated allografts were rejected after 7.3 ± 0.6 days as confirmed by H&E histology. There was an increase of serum kynurenine and a decrease of tryptophan concentrations as reflected by a significant increase of kyn/trp (day 2 post transplant: 18 ± 10; day 4: 21 ± 8; day 6: 43 ± 23; day 8: 37 ± 14) P < 0.05 at each timepoint. Intragraft expression of IDO mRNA was induced up to 100-fold on p.o. days 6 and 8. In contrast, animals receiving a syngeneic heart or allograft recipients treated with CsA did not show changes in kyn/trp (21 ± 5 and 19 ± 3 respectively) and expression profiles of IDO mRNA remained unchanged (syngeneic), or were attenuated by 2.6 ± 0.6 fold (CsA). IDO inhibition with 1-MT resulted in enhanced T-cell activity and was associated with progressive deterioration of the transplant followed by accelerated graft rejection (4.6 ± 0.8 days). Conclusion: Despite its tolerogenic effect in maternal immunity strong expression of IDO in cardiac allografts delays but does not prevent rejection. IDO activity, however, may serve as a novel marker of immune activation and via modulation of tryptophan catabolism offer a potential tool to abrogate the alloimmune response.

About this research paper

What this paper is about

P1142 Aims: Indoleamine 2,3-dioxygenase (IDO) via tryptophan depletion and the production of proapoptotic metabolites inhibits T-cell proliferation and leads to T-cell anergy. IDO is activated by INF-γ and has been demonstrated to play an essential role in maternal tolerance. The role of IDO in solid organ transplantation has not been clarified yet. Methods: Hearts of C57BL/10 (H-2b) mice were transplanted to C3H/He (H-2k) recipients. Syngeneic transplants and allograft recipients treated with CsA or with the IDO inhibitor 1-methyl tryptophan (1-MT) served as controls. Serum concentrations of kynurenine and tryptophan were analyzed by high performance liquid chromatography (HPLC) 2, 4, 6 and 8 days following transplantation. Kynurenine to tryptophan ratios (kyn/trp) were calculated as an indirect estimate of IDO activity. Intragraft IDO mRNA expression was assessed by quantitative RT-PCR (Taqman technology). Results: Untreated allografts were rejected after 7.3 ± 0.6 days as confirmed by H&E histology. There was an increase of serum kynurenine and a decrease of tryptophan concentrations as reflected by a significant increase of kyn/trp (day 2 post transplant: 18 ± 10; day 4: 21 ± 8; day 6: 43 ± 23; day 8: 37 ± 14) P < 0.05 at each timepoint. Intragraft expression of IDO mRNA was induced up to 100-fold on p.o. days 6 and 8. In contrast, animals receiving a syngeneic heart or allograft recipients treated with CsA did not show changes in kyn/trp (21 ± 5 and 19 ± 3 respectively) and expression profiles of IDO mRNA remained unchanged (syngeneic), or were attenuated by 2.6 ± 0.6 fold (CsA). IDO inhibition with 1-MT resulted in enhanced T-cell activity and was associated with progressive deterioration of the transplant followed by accelerated graft rejection (4.6 ± 0.8 days). Conclusion: Despite its tolerogenic effect in maternal immunity strong expression of IDO in cardiac allografts delays but does not prevent rejection. IDO activity, however, may serve as a novel marker of immune activation and via modulation of tryptophan catabolism offer a potential tool to abrogate the alloimmune response.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

P1142 Aims: Indoleamine 2,3-dioxygenase (IDO) via tryptophan depletion and the production of proapoptotic metabolites inhibits T-cell proliferation and leads to T-cell anergy. IDO is activated by INF-γ and has been demonstrated to play an essential role in maternal tolerance. The role of IDO in solid organ transplantation has not been clarified yet. Methods: Hearts of C57BL/10 (H-2b) mice were transplanted to C3H/He (H-2k) recipients. Syngeneic transplants and allograft recipients treated with CsA or with the IDO inhibitor 1-methyl tryptophan (1-MT) served as controls. Serum concentrations of kynurenine and tryptophan were analyzed by high performance liquid chromatography (HPLC) 2, 4, 6 and 8 days following transplantation. Kynurenine to tryptophan ratios (kyn/trp) were calculated as an indirect estimate of IDO activity. Intragraft IDO mRNA expression was assessed by quantitative RT-PCR (Taqman technology). Results: Untreated allografts were rejected after 7.3 ± 0.6 days as confirmed by H&E histology. There was an increase of serum kynurenine and a decrease of tryptophan concentrations as reflected by a significant increase of kyn/trp (day 2 post transplant: 18 ± 10; day 4: 21 ± 8; day 6: 43 ± 23; day 8: 37 ± 14) P < 0.05 at each timepoint. Intragraft expression of IDO mRNA was induced up to 100-fold on p.o. days 6 and 8. In contrast, animals receiving a syngeneic heart or allograft recipients treated with CsA did not show changes in kyn/trp (21 ± 5 and 19 ± 3 respectively) and expression profiles of IDO mRNA remained unchanged (syngeneic), or were attenuated by 2.6 ± 0.6 fold (CsA). IDO inhibition with 1-MT resulted in enhanced T-cell activity and was associated with progressive deterioration of the transplant followed by accelerated graft rejection (4.6 ± 0.8 days). Conclusion: Despite its tolerogenic effect in maternal immunity strong expression of IDO in cardiac allografts delays but does not prevent rejection. IDO activity, however, may serve as a novel marker of immune activation and via modulation of tryptophan catabolism offer a potential tool to abrogate the alloimmune response.

Key concepts: Kynurenine, Indoleamine 2,3-dioxygenase, Kynurenine pathway, Tryptophan, Transplantation, Messenger RNA, Immunology, Medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
INHIBITION OF THE IMMUNOMODULATORY ENZYME INDOLEAMINE 2,3–DIOXYGENASE ACCELERATES ALLOGRAFT REJECTION. — Research Paper | ScholarLens